Basket | Login


News & press


Pharmacog Logo


10 February: ExonHit choisie pour faire partie du consortium européen « Initiative Médicaments Innovants » sur la maladie d'Alzheimer.

12 February: Alzprotect au coeur du plus grand consortium Européen dans le domaine d’Alzheimer.

11 March: PharmaCog: quatre PME dans la cour des grands.

1 November: Lancement du site Internet du Projet Européen IMI PharmaCog.

14 November: ICDD, partner of Pharmacog IMI consortium.

Pharmacog Logo


7 April: Maladie d’Alzheimer: réflexion d’une quarantaine de chercheurs du consortium européen «Pharmacog» sur les outils nécessaires pour rationaliser la découverte de médicaments innovants contre cette maladie.

29 April: Servier collabore au projet Pharmacog dans la recherche contre la maladie d'Alzheimer.

5 June: PharmaCog: €20 million against Alzheimer's.

6 June: PharmaCog, a model for pre-competitive partnership at WPC.

20 July: Qualissima est membre du consortium européen PharmaCog.

21 September: Lutte contre la maladie d'Alzheimer: l'Union européenne en première ligne.

Pharmacog Logo


2 February: Résultats préliminaires du projet PharmaCog.

23 February: Bristol University joins PharmaCog.

Pharmacog Logo


23 May: Pharma-Cog and EMIF-AD projects bring Alzheimer's treatments closer to reality.


12 July: PharmaCog partners at the AAIC conference

Various PharmaCog researchers presented project results and posters at the AAIC 2014 conference, which took place during 12-16 July in Copenhagen, Denmark.

Claudio Babiloni presented "On-going frontal alpha rhythms are dominant in passive state and desynchronize in active state in adult gray mouse lemurs" and “'Men and mice' written by PharmaCog: Can EEG markers of Alzheimer’s disease be back-translated to mouse models?"

Dr Babiloni also presented three posters:

  • "Frontal cortical sources of auditory oddball event-related potentials are related to cerebrospinal fluid β amyloid in amnesic MCI subjects"
  • "Cortical sources of resting state eyes closed EEG rhythms are correlated to cerebrospinal fluid β amyloid in amnesic MCI subjects"
  • "Effects of donepezil on EEG-EMG markers in wild type (WT) and triple transgenic (TauPS2APP) mice EEG markers of motor activity in mice in physiological and pathological aging"

Esther Schenker presented the poster "In vivo microdialysis reveals (age-dependent) modification of frontocortical interstitial fluid levels of amyloid b1-40, b1-42, tau and other 'classical' neuromodulators in different strains of transgenic mice".

In November 2014, Dr Schenker will present the poster "Age-dependent changes of beta-amyloid and tau protein in two mouse models of Alzheimer’s disease" at the Neuroscience 2014 conference in Washington, DC.


18 December: Final meeting of the PharmaCog Steering Committee

The members of the PharmaCog Steering committee held their final meeting on 18 December in Lille (France), as the project will finish at the end of the year. The partners discussed the final results of the various work packages and how these would be presented in the last yearly report to IMI – the Innovative Medicines Initiative.

Dr Jill Richardson and Dr Régis Bordet, respectively the  EFPIA and academic coordinators of the project, thanked the participants from all the work packages for their valuable work and looked forward to potential further collaboration in future projects.

The PharmaCog partners have developed models to predict the efficacy of drug candidates by combining past and current data to define a series of biomarkers of dementia progression. Alzheimer Europe was an active partner in communication and dissemination activities and will continue to update the project website in 2016.

3 October: PharmaCog researchers show progress at ECCN conference

The PharmaCog project was very well represented at ECCN, the 15th European Congress on Clinical Neuro­physiology that took place in Brno, Czech Rep. during 30 September - 3 October 2015.

Susanna Lopez presented the following papers:

  • “Auditory oddball event-related potentials cortical sources are related to cerebrospinal fluid (CSF) β Amyloid (Aβ) level in amnesic MCI subjects.”
  • “Abnormal delta cortical sources of resting state eyes closed EEG rhythms correlate with cerebrospinal fluid (CSF) β Amyloid (Aβ) level in amnesic MCI subjects.”
  • “EEG markers of motor activity in physiological aging and Alzheimer's disease mouse models.”

Claudio Babiloni presented:

  • "Of Mice and Men: impact of Alzheimer‘s disease on cortical generation of EEG rhythms in mice and humans towards a true translational mode.”
  • “Cortical Generation of On-going "Delta" and "Alpha" EEG Rhythms in Mouse Models of Alzheimer‘s disease and Alzheimer’s disease Patients at Prodromic and Manifest Stages.”

Wilhelmus Drinkenburg presented “Pharmacological Neuromodulation of on-going "Delta" and "Alpha" EEG Rhythms: Evidence for Translational Neurophysiological Biomarkers in Alzheimer‘s Disease Animal Models.”

The PharmaCog project is developing models to predict the efficacy of drug candidates by combining past and current data to define a series of biomarkers of dementia progression. The project aims to propose to the pharmaceutical industry and academic research laboratories new methods for successfully developing new drugs for the treatment of Alzheimer's disease.

28 June: PharmaCog researchers show results at EACPT conference

PharmaCog researchers Claudio Babiloni, David Bartrés-Faz, Régis Bordet and Pablo Martinez Lage (pictured L-R) all attended the 12th biennial Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), which was held in Barcelona on 27-30 June.

Alzheimer’s disease was the focus of a key session of the conference, including presentations by Dr Bordet (Disease modifiers in Alzheimer's disease: towards a multimodal strategy) and Dr Bartrés-Faz (How cognitive challenge models can improve the sensitivity of the biomarker battery to test symptomatic treatments: the PharmaCog project approach).

The four colleagues also featured in an interview where they discussed the development of new treatments and why previous treatment approaches may not have worked. They also presented PharmaCog’s approach to develop new biomarkers in order to speed up successful drug development. The 20+ minute interview is available on YouTube.

25 February: PharmaCog partners hold Steering Committee meeting

The members of the PharmaCog Steering Committee held a meeting in Lille, France on 25 February. The meeting was hosted by Prof Régis Bordet (Academic Coordinator) and mainly focused on the final presentations of the pre-clinical work packages. The delegates also discussed their input to the 2014 project report.

The PharmaCog partners are developing models to predict the efficacy of drug candidates by combining past and current data to define a series of biomarkers of dementia progression. The project began in 2010 and is now in its final year.



Last Updated: Friday 09 May 2014


  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations